VFA
ABUS icon

Valeo Financial Advisors’s Arbutus Biopharma ABUS Stock Holding History

Valeo Financial Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,000
Closed -$25K – 1657
2020
Q3 		$25K Buy
+8,000
New +$24.3K ﹤0.01% 860

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Valeo Financial Advisors's ABUS Position: Q4 2020 in Review

Valeo Financial Advisors sold out of Arbutus Biopharma (ABUS) in Q4 2020, closing a stake of 8,000 shares — an estimated $25K sold.

Valeo Financial Advisors first reported a position in ABUS in Q3 2020 and held it in 1 quarter. The position peaked at $25K in Q3 2020. 80 funds tracked by Wall St. Rank hold ABUS as of Q4 2020.

  • Valeo Financial Advisors reported no remaining Arbutus Biopharma position as of Q4 2020 after selling out during the quarter.
  • Valeo Financial Advisors sold 8,000 Arbutus Biopharma shares in Q4 2020, an estimated $25K.
  • Valeo Financial Advisors first reported a position in Arbutus Biopharma in Q3 2020 and held it in 1 quarter.
  • Valeo Financial Advisors's Arbutus Biopharma position peaked at $25K in Q3 2020.
  • 80 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2020.

Based on Valeo Financial Advisors's 13F filing for Q4 2020, filed 11 Feb 2021.